NASDAQ · Biotechnology

NeuroSense Therapeutics Ltd. (NRSN) Stock

$2.46 +0.82% NASDAQ: NRSN Healthcare

Valuation

MetricValue
Price$2.46
Market Cap$4.67M
P/E Ratio-0.36
P/B Ratio-2.10
P/S Ratio0.00
EPS (TTM)$-0.44
52-Week High$25.40
52-Week Low$2.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE723.04%
ROA-853.16%
ROCE587.30%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.11
Current Ratio0.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-6.0M$-14.0M$-12.0M$-10.0M$-11.0M
Net Profit$-4.0M$-12.0M$-10.0M$-10.0M$-11.0M
EPS$-4.60$-21.40$-16.60$-11.00$-8.80
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$8.0M$3.0M$5.0M$1.0M
Total Liabilities$2.0M$2.0M$5.0M$2.0M$3.0M
Cash$11.0M$4.0M$3.0M$3.0M$0
Borrowings$0$0$0$0$0

Latest News

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire · Jul 6, 2026 NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint MT Newswires · Jun 29, 2026 NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PR Newswire · Jun 29, 2026 NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PR Newswire · Jun 25, 2026 EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PR Newswire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-8.0M$-8.0M$-10.0M$-8.0M
Investing Cash Flow$0$-4.0M$3.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$10.0M$-8.0M$-1.0M$1.0M$-3.0M
Free Cash Flow$-2.0M$-8.0M$-8.0M$-10.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-0.56
FCF Yield-75.70%
Quick Ratio0.31
Interest Coverage-1028.12
Return 1Y-63.69%
Return 3Y-47.14%
Return 5Y—

Ownership

Insiders Held32.31%
Institutions Held1.07%
Institutions Float Held1.59%
Institutional HolderSharesReport Date
Yorkville Advisors Global, LP78,0002026-03-31
UBS Group AG49,0962026-03-31
Independent Advisor Alliance50,0002026-03-31
Two Sigma Investments, LP44,4452026-03-31
Meitav Investment House Ltd.40,0002026-03-31

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is led by CEO Alon Ben-Noon, employs 17 people, headquartered in IL, publicly traded since 2021.

NeuroSense Therapeutics Ltd. (NRSN) stock trades at $2.46 with a market capitalization of $4.67M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.36, reflecting a net loss over the last twelve months, a negative price-to-book of -2.10, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.19 and $25.40, and currently trades 90.3% below its 52-week high.

On profitability, NeuroSense Therapeutics Ltd. generates a return on equity (ROE) of 723.04% (not meaningful, as shareholders' equity is negative), return on capital employed of 587.30%.

NeuroSense Therapeutics Ltd. by the numbers, 2019–2025

Between 2019 and 2025 NeuroSense Therapeutics Ltd. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-11.0M.

On a trailing twelve-month basis to Dec '25, revenue is $0 and net profit $-10.0M.

Borrowings stand at $0, cash from operations was $-8.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged 94.5% over five years, and was 550.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

NeuroSense Therapeutics Ltd. (NRSN) — frequently asked questions

What is NeuroSense Therapeutics Ltd. (NRSN) stock price today?

NeuroSense Therapeutics Ltd. (NRSN) is currently trading at $2.46, up 0.82% today.

What is NRSN P/E ratio?

NeuroSense Therapeutics Ltd.'s P/E ratio is -0.36. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is NRSN return on equity (ROE)?

NeuroSense Therapeutics Ltd.'s return on equity (ROE) is 723.04%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is NeuroSense Therapeutics Ltd.'s market cap?

NeuroSense Therapeutics Ltd. has a market capitalization of $4.67M.

Does NRSN pay a dividend?

NeuroSense Therapeutics Ltd. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does NRSN carry?

NeuroSense Therapeutics Ltd. has a debt-to-equity ratio of -0.11. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is NRSN's profit margin?

NeuroSense Therapeutics Ltd. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is NRSN in?

NeuroSense Therapeutics Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is NRSN listed on?

NeuroSense Therapeutics Ltd. trades on NASDAQ under the ticker NRSN.

What is NRSN's 52-week range?

Over the last year NeuroSense Therapeutics Ltd. has traded between $2.19 and $25.40.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens NRSN currently matches

On the figures above, NeuroSense Therapeutics Ltd. passes the filters for 2 of our ready-made screens, among them Penny Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksNano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.